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Abstract: Recent advancement in the field of molecular cancer research has clearly revealed that
abnormality of oncogenes or tumor suppressor genes causes tumor progression thorough the
promotion of intracellular metabolism. Metabolic reprogramming is one of the strategies for cancer
cells to ensure their survival by enabling cancer cells to obtain the macromolecular precursors and
energy needed for the rapid growth. However, an orchestration of appropriate metabolic reactions
for the cancer cell survival requires the precise mechanism to sense and harness the nutrient in the
microenvironment. Mammalian/mechanistic target of rapamycin (mTOR) complexes are known
downstream effectors of many cancer-causing mutations, which are thought to regulate cancer
cell survival and growth. Recent studies demonstrate the intriguing role of mTOR to achieve the
feat through metabolic reprogramming in cancer. Importantly, not only mTORC1, a well-known
regulator of metabolism both in normal and cancer cell, but mTORC2, an essential partner of
mTORC1 downstream of growth factor receptor signaling, controls cooperatively specific metabolism,
which nominates them as an essential regulator of cancer metabolism as well as a promising candidate
to garner and convey the nutrient information from the surrounding environment. In this article,
we depict the recent findings on the role of mTOR complexes in cancer as a master regulator of cancer
metabolism and a potential sensor of nutrients, especially focusing on glucose and amino acid sensing
in cancer. Novel and detailed molecular mechanisms that amino acids activate mTOR complexes
signaling have been identified. We would also like to mention the intricate crosstalk between glucose
and amino acid metabolism that ensures the survival of cancer cells, but at the same time it could be
exploitable for the novel intervention to target the metabolic vulnerabilities of cancer cells.
Keywords: mTOR complex; metabolic reprogramming; cancer; microenvironment; nutrient sensor
1. Introduction
Proliferating cells require not only adenosine triphosphate (ATP) as an essential energy source,
but also intracellular building blocks including nucleotides, fatty acids, and proteins, and a
reprogrammed metabolism could serve to support the synthesis of macromolecules [1,2]. The Warburg
effect is a hallmark phenomenon of cancer metabolism and relies on aerobic glycolysis to generate
the energy needed for an array of cellular processes in contrast to normal differentiated cells on
mitochondrial oxidative phosphorylation [3,4]. In other words, cancer cells are heavily dependent
and addicted to glucose metabolism for their survival. Amino acids are another major determinant to
support cancer cell proliferation. For example, cancer cells take up glutamine to survive or proliferate
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by promoting the production of nucleotides, fatty acids, and proteins [5–7], an anaplerotic process that
replenishes a metabolic cycle.
Cancer cells take up a large amount of amino acids and glucose from the extracellular environment
as a carbon and nitrogen source for protein and nucleotide synthesis [1,8]. In the process of tumor
initiation and progression, cancer cells are exposed to harsh conditions such as hypoxia or nutrient
depletion in the tumor microenvironment. To survive in this severe environment, cancer cells must
sense and respond to the status of nutrient availability in the extracellular environment to coordinately
regulate the gene expression for sustaining the cell proliferation as well as everting the various stress
that halts the cell proliferation and induce cell death [9–11]. Thus, unveiling the mechanisms how
cancer cells gather the information on environmental nutrient and facilitate their survival would shed
new light on the molecular pathogenesis of cancer progression, which could be harnessed to identify
the unrecognized addiction and vulnerability.
Here, we focus on mammalian/mechanistic target of rapamycin (mTOR) complexes, essential
regulator of cell proliferation and metabolism, as a potential key player to play a role in
sensing nutrients to drive the intracellular tumor-promoting signaling cascade through metabolic
reprogramming and epigenetic shift, and a key node which should be therapeutically targeted as a
new mode of treatment to interfere with cancer cell metabolism.
2. Metabolic Reprogramming as an Essential Hallmark in Cancer
The hallmarks of cancer are composed of six biological capabilities, which are acquired during
the multistep evolution of human neoplasms [12]. The complexities of neoplastic disease are well
explained by fundamental principles of the cancer hallmarks. Metabolic reprogramming is an emerging
core hallmark of cancer [12], and similar alterations are also observed in rapidly proliferating cells such
as immune cells under patho-physiological conditions [13]. Various intrinsic and extrinsic molecular
signaling shifts the intracellular metabolism to support the demands of rapidly proliferating cells,
including ATP generation to maintain energy, biosynthesis of macromolecules, and maintenance
of reduction-oxidation (redox) reaction. The central hallmark of this reprogramming lies in the
phenomenon that cancer cells undergo glycolysis even in the presence of sufficient oxygen, termed “the
Warburg effect,” and there has been much interest in examining and comprehending the pathways that
regulate the survival advantages conferred by this aerobic glycolysis [3]. Over the past decade, however,
far more complex aspects of cancer metabolism have emerged, and the Warburg effect alone cannot
well explain all the metabolic changes required for rapid cell growth, including aerobic glycolysis,
glutaminolysis, altered lipid metabolism, de novo nucleic acid synthesis, and reactive oxygen species
(ROS) management. For instance, as for ROS metabolism, nutrient deficiency, glucose deprivation
and hypoxia induce ATP reduction and ROS overproduction, which could promote metabolic
reprogramming in cancer cells [14]. Of interest, activated mTORC1 increased the level of ROS [15],
suggesting that mTOR complex induces metabolic reprogramming via ROS production in response to
unpreferable environments for cancer cells. On the contrary, mTORC1 regulates superoxide dismutase
1 (SOD1) activity through reversible phosphorylation in response to nutrients, which moderates ROS
level and prevents oxidative DNA damage [16], and mTORC2 regulates the production of reduced
form of nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH), which could
counteract the overproduction of ROS [17]. Further, epigenetic landscape including a shift in DNA and
histone modifications are shaped and modulated by intermediary metabolites produced via metabolic
reprogramming [13]. Therefore, the dynamic plasticity of metabolic reprogramming and epigenetic
shift can converge to confer the survival advantage to cancer cells, but these alterations also render
cancer cells vulnerable to interference with the metabolic and epigenetic network. Deciphering the
molecular mechanism of the metabolic and epigenetic regulations in cancer could pave the way for
therapeutic intervention, and the recent emerging evidences have revealed the essential regulatory
role of mTOR complexes in metabolic reprogramming, the responsibility to microenvironments, and
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the subsequent epigenetic changes, which can result in cell survival in harsh metabolic conditions and
provide therapeutic opportunities in cancer.
3. mTORC1 and mTORC2-Irreplaceable Partners in Cancer Metabolic Reprogramming
Genetic mutations to constitutively activate phosphoinositide 3-kinase (PI3K)-Akt-mTOR
signaling are reported to reprogram cellular metabolism and tumorigenesis, including receptor
tyrosine kinase (RTK) amplification and mutations, phosphatidylinositol 4,5-bisphosphate 3-kinase
catalytic subunit alpha isoform (PIK3CA) mutation and phosphatase and tensin homolog deleted
from chromosome 10 (PTEN) loss [18]. Among them, as a serine/threonine protein kinase essential
for the cellular function, two distinct multi-protein complexes of mTOR associate the signaling from
growth factor receptor with cell growth, proliferation, and survival. mTOR complex 1 (mTORC1),
an established druggable target against cancer, phosphorylates and controls its substrates p70
ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1
(4E-BP1) to promote protein translation as well as anabolic metabolism downstream of growth factor
receptor-activated PI3K-Akt signaling [19,20]. The important role of mTOR complex 2 (mTORC2)
has been gradually unraveled, especially in the field of metabolic homeostasis and cancer biology.
mTORC2 has been considered to be responsive to growth factor signaling and the interaction of
ribosome, and to function mainly through activating Akt by phosphorylating it on serine 473
(Ser473) [21,22]. It can also phosphorylate other AGC subfamily kinases including serum and
glucocorticoid-inducible kinase 1 (SGK1) and protein kinase C (PKC). Recent studies demonstrated
that mTORC2 regulates tumor progression, chemotherapy resistance, and genome DNA stability in
cancer cells, playing an unrecognized, essential role in cancer biology [23,24]. Of note, these effects
appear to be independent from canonical Akt-mediated signaling [25], indicating the importance of
mTORC2 itself in cancer biology.
The structures of mTORC1 and mTORC2 are characterized by sharing some components: they
share the catalytic mTOR subunit, as well as mammalian lethal with sec-13 (mLST8, also known
as GβL) [26,27], the DEP domain containing mTOR-interacting protein (DEPTOR) [28], and the
Tti1/Tel2 complex [29]. In contrast, regulatory-associated protein of mammalian target of rapamycin
(raptor) [30,31] and proline-rich Akt substrate 40kDa (PRAS40) [32–35] are specific to mTORC1,
while rapamycin-insensitive companion of mTOR (rictor) [26,36], mammalian stress-activated map
kinase-interacting protein 1 (mSin1) [37,38], and protein observed with rictor 1 and 2 (protor1/2) [33,
39,40] are specific components of mTORC2.
Oncogenes and tumor suppressors are a key determinant in controlling cancer metabolism [41–43].
In various types of cancers, growth factor receptor signaling converges to an oncogenic transcription
factor c-Myc, which promotes cell proliferation via metabolic reprogramming to connect nutrient
uptake with intracellular biomass accumulation [44–46]. We recently identified that cancer cell
metabolism was promoted through c-Myc which could be activated cooperatively by both mTORC1
and mTORC2 [47]. In glioblastoma (GBM, a malignant glial/astrocytic tumor) cells with activating
epidermal growth factor receptor (EGFR) mutations, mTORC1 upregulates the heterogeneous nuclear
ribonucleoprotein A1 (hnRNPA1) splicing factor, promoting the alternative splicing of Myc-associated
factor X (Max) to generate Delta Max, thereby functionally augmenting Myc-dependent glycolytic
metabolism and tumor cell proliferation [48]. mTORC2, on the other hand, increases the transcription
of c-Myc through inhibitory phosphorylation of class IIa histone deacetylases (HDACs), resulting in
inactivation of forkhead box O (FoxO) transcription factors through post-translational acetylation [47].
Therefore, growth factor receptor-PI3K signaling requires the synergistic action of mTORC1 and
mTORC2 for c-Myc-dependent metabolic reprogramming by controlling both c-Myc transcription
and its functional activity (Figure 1). Considering the essential and coupling roles of two mTOR
complexes in reprogramming cancer cell metabolism, the next critical questions would be raised how
mTOR complexes could sense the information on the source of metabolic reactions (i.e., nutrients) and
subsequently respond to the microenvironmental condition to favor their survival.
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mTORC1/2: mammalian/mechanistic target of rapamycin complex 1/2; HDAC: histone deacetylase; 
hnRNPA1: heterogeneous nuclear ribonucleoprotein A1; Max: myc-associated factor X; FoxO: 
forkhead box O; Ac: acetyl-group. 
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catabolic processes and by driving cell cycle progression through phosphorylating its substrates 
[52,53]. However, when amino acid supplies become restricted, the activity of mTORC1 is 
significantly suppressed, and mammalian cells employ homeostatic mechanisms to rapidly inhibit 
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Figure 1. EGFRvIII controls c-Myc through two interlacing and synergistic mechanisms.
EGFRvIII-mTORC1 signaling promotes glycolytic metabolism by activating hnRNPA1-dependent
alternative splicing of a Myc-binding partner Delta Max, thereby functionally augmenting the oncogenic
activity of c-Myc. Alternatively, EGFR-mTORC2 signaling controls c-Myc transcription, translation and
protein level through FoxO acetylation, resulting in the enhancement of metabolic reprogramming.
These findings point to the central role of c-Myc in regulating EGFRvIII-activated glycolytic metabolism.
EGFRvIII: epidermal growth factor receptor variant III; PI3K: phosphoinositide 3-kinase; mTORC1/2:
mammalian/mechanistic target of rapamycin complex 1/2; HDAC: histone deacetylase; hnRNPA1:
heterogeneous nuclear ribonucleoprotein A1; Max: myc-associated factor X; FoxO: forkhead box O;
Ac: acetyl-group.
4. mTORC1 as a Sensor of Amino Acids in Cancer Cells
mTORC1 is an evolutionarily conserved multi-protein complex that coordinates a network of
signaling cascades and functions as a key mediator of protein translation, gene transcription, and
autophagy [49–51]. mTORC1 is activated by growth factors such as insulin, and nutrients such as
amino acids, which eventually promote cell growth and proliferation by regulating anabolic and
catabolic processes and by driving cell cycle progression through phosphorylating its substrates [52,53].
However, when amino acid supplies become restricted, the activity of mTORC1 is significantly
suppressed, and mammalian cells employ homeostatic mechanisms to rapidly inhibit processes such
as protein synthesis, which demands high levels of amino acids. Additionally, mTORC1 supplies amino
acid resource through releasing the suppression of autophagy under a starved state [54]. Of interest,
the amino acid sensing mechanism that non-cancer cells use via mTORC1 could be exploited by
cancer cells as described in the following sections, and the future endeavor should be directed to
examine if there is actually a difference between cancer and non-cancer cells for amino acid sensing
through mTORC1.
Leucine, one of the essential amino acids in human cells, mainly induces the recruitment of
mTORC1 to the lysosomal membrane and its subsequent activation; that is, mTORC1 is activated
in response to the level of leucine [55]. Leucine is also a signaling molecule that directly regulates
animal physiology, including satiety [56], insulin secretion [57], and skeletal muscle anabolism [58,59].
Signal transduction through mTORC1, which is involved in cell growth through enhanced protein
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translation, is activated by extracellular leucine through Sestrin1/2, a GATOR2-interacting protein
that inhibits mTORC1 signaling [55,60] (Figure 2). In addition to sensing leucine for its activation,
CASTOR proteins were identified as a putative arginine sensor for the mTORC1 pathway, which is
activated by extracellular arginine and interacts with GATOR2 and activate mTORC1 via promotion of
the hetero-dimerization of GTP-RagA and GDP-RagC [61] (Figure 2).
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Figure 2. Mechanism of mTORC1 activation via Rag proteins by amino acids. mTORC1 is transferred
to lysosome from cytosol by promoting heterodimerization of GTP-binding Rag proteins, which work
as mediators of amino acid signaling to mTORC1. It is then activated by binding to GTP-bound
Rheb on lysosome. Extracellular arginine and leucine activate RagA-RagC heterodimer, GTP-binding
RagA, and GDP-binding RagC via amino acid transporter CASTOR1/2 and Sestrin1/2 to transfer
mTORC1 to lysosome. Lysosomal arginine also activates Rag heterodimer via lysosomal amino acid
transporter SLC38A9.
Recent studies also demonstrate the intriguing interaction of amino acid metabolism and mTORC1
signaling through the ubiquitin signaling systems, displaying that, in response to amino acids,
the KLHL22 E3 ubiquitin ligase promotes K48-linked polyubiquitination, enabling mTORC1 signaling
to promote tumorigenesis and aging [62]. Another interesting example is SAMTOR, which was
reported to inhibit mTORC1 signaling by interacting with GATOR1, the GTPase activating protein
(GAP) for RagA/B [63]. Notably, the methyl donor S-adenosylmethionine (SAM) disrupts the
SAMTOR-GATOR1 complex, and methionine-induced activation of mTORC1 requires the SAM
binding capacity of SAMTOR, indicating that mTORC1 is involved in methionine and one-carbon
metabolism, which potentially control the epigenetic (methylation) shift in cancer. mTORC1 could
thus respond to a range of amino acids and relevant metabolites, the mechanism of which could be
involved in multiple human disease conditions including cancer. Importantly, the insufficiency for new
protein synthesis is actively monitored by both prokaryotic and eukaryotic cells, and these amino acid
sensing mechanisms described here might be an Achilles heel in cancer, which could be exploitable for
the novel therapeutic strategies against cancer [64].
5. mTORC2 at the Intersection of Glucose and Amino Acid Metabolism
Cancer cells convert the majority of glucose into lactate even under ample oxygen (the
Warburg effect), the products of which could be used as carbon-containing precursors for the
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macromolecule production by rapidly proliferating cells. This intriguing phenomenon necessitates
the presence of “glucose sensor” in cancer cells to precisely catch the information on the glucose in
the microenvironment for appropriately responding to the environment and ensuring their survival.
In recent years, several fascinating reports have been published, referring to the relationship between
mTORC2, metabolic reprogramming, and nutrient sensing in cancer cells. mTORC2 is activated on
the high-glucose extracellular condition via acetylation of Rictor, the main component of mTORC2
in human GBM cells [65] (Figure 3). This is metabolically mediated by the increased production
of acetyl-coenzyme A (acetyl-CoA), a well-known donor of the acetyl group to the protein [66].
The findings suggest the possibility that mTORC2 could work as a potential glucose sensor in
cancer cells.
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Figure 3. The function of mTORC2 as a sensor of glucose and amino acid. mTORC2 is activated
by glucose through acetylation of Rictor, playing a role as a sensor of glucose. Phosphorylation of
Ser26 of xCT by mTORC2 represses its function as glutamate-cystine anti-transporter. Under nutrient
(glucose) poor conditions, lower mTORC2 signaling could tilt the balance from proliferation to survival
by favoring glutamate efflux, cystine uptake, and glutathione synthesis to protect tumor cells from
cellular stress.
Unlike mTORC1, which works as an amino acid sensor, the role of mTORC2 as a sensor of
amino acid has yet to be clarified. However, using an unbiased proteomic screen, our recent work
unraveled that mTORC2 could suppress the activity of the cystine-glutamate antiporter, system Xc
transporter-related protein (xCT) via inhibitory phosphorylation of serine 26 of xCT’s N terminus
cytosolic domain [67] (Figure 3). These results identify an unanticipated mechanism regulating amino
acid metabolism in cancer, indicating that genetic mutations and aberrant signal transduction in cancer
cells could reprogram amino acid metabolism. Additionally, this novel system would implicate the
new role of mTORC2 as a potential amino acid sensor. Glutamine uptake, promoted by aberrant
growth factor receptor and c-Myc signaling, is important for tumor cell proliferation, since it is
subsequently converted to glutamate essential for tricarboxylic acid (TCA) cycle anaplerosis to provide
a carbon source for proliferating cancer cells [65,68]. Thus, when the levels of exogenous nutrient are
sufficiently high to support cancer cell proliferation, it would be of disadvantage for cancer cells to
secrete glutamate, which is necessary for their anaplerotic reactions. Recently identified mechanisms
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here enable glutamine-derived glutamate to be utilized primarily for tumor cell proliferation when
nutrients are rich in the tumor microenvironment. On the other hand, it would be an advantage
for cancer cells to increase xCT-dependent cystine uptake in exchange for glutamate efflux, enabling
tumor cells to neutralize the cellular oxidative stresses by synthesizing glutathione from xCT-derived
cysteine, when extracellular nutrients are lacking. Therefore, the mechanism on amino acid metabolism
described here makes it possible for cancer cells to respond and adapt to a dynamic shift in nutrient
levels in the tumor microenvironment.
An unexpected implication for cancer cell metabolism comes from these recent studies regarding
the sensing mechanism of glucose and amino acid by mTORC2. Exogenous nutrients including
glucose and acetate have been reported to activate mTORC2 to phosphorylate its downstream
substrates as aforementioned [69], and this mTORC2-dependent glucose sensing mechanism would
raise the possibility that, when extracellular nutrients become scarce, lower mTORC2 signaling
could tilt the balance of tumor cell status from cell proliferation to cell survival, at least partly by
preferring glutamate efflux, cystine uptake, and glutathione synthesis in order to protect tumor cells
from the oxidative cellular stresses, the mechanism of which is based on the mTORC2-dependent
regulation of xCT systems (Figure 3). The findings provide the challenging and promising ideas on the
previously unrecognized interaction between glucose and amino acid metabolism through mTORC2
signaling, which enables cancer cells to promote their survival according to the level of nutrients in
the microenvironment.
6. Epigenetic Modulation by mTOR-Dependent Metabolism in Cancer
Many enzymes that play important roles in epigenetic gene regulation utilize intermediary
metabolites as co-substrates yielded by cellular metabolic reprogramming [70]. Indeed, epigenetic
modifiers are sensitive to alterations in the levels of multiple intermediary metabolites, which can be
regulated by PI3K/Akt/mTOR signaling.
Acetylation on the N-terminal lysine tail of histones leads to the neutralization of positively
charged lysine with an open chromatin configuration facilitating transcription. On the other side of the
coin, deacetylation of histones is associated with condensed chromatin and reduction of transcriptional
activity. Acetyl-CoA is the substrate used to modify histone tails, and can be produced through a
variety of metabolic pathways. Its primary generation sources are through the conversion of pyruvate
from glycolysis and citrate from the TCA cycle. Intriguingly, some of the processes seem to be
governed by the RTK/PI3K/Akt/mTOR pathway, thus possibly linking their metabolic processes to
epigenetic status. Recent studies demonstrated that dynamic translocation of mitochondrial pyruvate
dehydrogenase complex (PDC) to the nucleus provides a pathway for nuclear acetyl-CoA synthesis
required for histone acetylation and epigenetic regulation [71]. Interestingly, the nuclear translocation
of PDC seems to be facilitated by the stimulation of growth factor receptor signaling, and it may be
mediated by mTOR pathway signaling. ATP citrate lyase (ACLY) is a key enzyme responsible for
generating cytosolic acetyl-CoA and oxaloacetate. Akt enhances the phosphorylation and activation of
ACLY, and ACLY inhibition results in tumor growth arrest [72]. ACLY is also regulated by growth factor
stimulation, which is required for histone acetylation and gene expression [73]. Thus, recent discoveries
that class IIa HDACs (HDAC4, 5, 7, and 9) are involved in glucogenic metabolic processes [74] and
are regulated by mTORC2 [47] suggest that mTORC2 may affect histone acetylation directly or
indirectly through the regulation of acetyl-CoA producing as well as histone modifying enzymes.
Intracellular acetyl-CoA also derives from β-oxidation of fatty acids. Recent work has highlighted
the importance of fatty acid catabolism in cellular energy homeostasis, and it may also affect the
epigenetics through the production of acetyl-CoA. In cancer cells, a gene expressed only in the brain,
carnitine palmitoyltransferase 1C, was reported to promote fatty acid oxidation and cell survival,
and confer rapamycin resistance, indicating that this gene may act in parallel to mTOR-enhanced
glycolysis [75].
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In addition to histone acetylation, histone methylation is also important in defining the epigenetic
state of chromatin as well as the methylation of DNA itself. A methyl-donor SAM derived from
methionine is utilized by methyltransferases; thus, its metabolism can profoundly affect the DNA and
histone methylation status. Methionine adenosyltransferase (MAT) is an essential enzyme responsible
for SAM biosynthesis, and the function and subclass switch of MAT can be associated with PI3K/Akt
signaling, affecting global DNA methylation and cell survival in cancer [76]. Recently, HDAC4 (class
IIa HDAC) is reported to play a central role for histone methylation in response to cardiac load,
revealing a new relationship between HDACs and histone methylation [77], so mTORC2 might be
involved in the regulation of global histone methylation through the inhibition of class IIa HDACs [47].
Somatic mutation of the NADP(+)-dependent enzyme isocitrate dehydrogenase (IDH) is
frequently found in cancer, and is shown to acquire a neomorphic enzymatic activity that converts
α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG) [78]. Oncometabolite 2-HG was shown to affect
the epigenetic status through the inhibition of α-KG-dependent dioxygenase/DNA demethylase
(TET2) for DNA methylation and the Jumonji-domain-containing protein 2A (JMJD2A/KDM4A) for
histone methylation, eventually contributing to the genome-wide methylator phenotype (CIMP: CpG
island methylator phenotype). 2-HG also activates the EGLN1 prolyl hydroxylase and increases the
degradation of HIF. The PI3K/Akt/mTOR pathway is relevant to HIF regulation [13], which might
further connect metabolism to epigenetics through the control of epigenetic enzymes by HIF and
counter-balance the IDH-mediated epigenetic changes. Intriguingly, recent reports demonstrated
that DNA methylation landscape of cancer progression shows extensive heterogeneity in time and
space [79,80], and further comprehension of these relationships will help our understanding of the
mechanics of a variety of metabolic diseases including cancer.
7. Molecular Therapies Targeting mTOR-Dependent Signaling and Metabolism
Understanding the complex role of mTOR in regulating signal transduction is critical to
developing more effective therapies to target metabolic reprogramming in cancer. Distinctly, rapamycin
treatment (a macrolide antibiotic and immunosuppressive compound that inhibits mTORC1 signaling)
leads to the release of Akt suppression (hence activation of mTORC2), due to the loss of negative
feedback for attenuating PI3K signaling [81]. The PI3K pathway reactivation after rapamycin treatment
indicates that dual PI3K/mTOR inhibitors function by preventing PI3K signaling reactivation and more
effectively target mTORC2 (and mTORC1) signaling [82]. Our study further sheds light on the resistant
mechanisms of GBM to targeted therapies, providing compelling rationale for the combined inhibition
of PI3K/Akt and mTORC2 as a promising “combinatorial targeted therapy” for targeting cancer
cell metabolism [83] (Figure 4). We recently demonstrated that EGFRvIII and loss of PTEN potently
activate mTORC2, resulting in GBM cell growth and survival by activating NF-κB through SGK1.
This study also identified a previously unsuspected role for mTORC2 in mediating chemotherapy
resistance, and EGFRvIII-expressing GBMs are exquisitely resistant to cisplatin, temozolomide, and
etoposide [24]. These results strongly suggest a critical role for drugs that target both mTORC1 and
mTORC2, including in combination with chemotherapy.
mTOR also plays a critical role in integrating cellular metabolism with signal transduction.
mTORC1 has emerged as a critical effector downstream of the tumor suppressor liver kinase
B1 (LKB1). LKB1 is thought to suppress tumor formation by negatively regulating mTORC1
signaling through adenosine monophosphate (AMP)-activated protein kinase (AMPK). A study by our
group demonstrated that the AMPK activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside
(AICAR) effectively blocks the growth of EGFR-activated GBM primarily by inhibiting lipogenesis [84]
(Figure 4). We also demonstrated that EGFR signaling promotes activation of the transcriptional
regulator of fatty acid synthesis, sterol regulatory element-binding protein-1 (SREBP-1) [85].
Further investigation uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival
pathway through the low-density lipoprotein receptor (LDLR) [86]. Targeting LDLR with the liver X
receptor (LXR) agonist caused an inducible degrader of LDLR (IDOL)-mediated LDLR degradation and
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increased expression of the ATP-binding cassette protein A1 (ABCA1) cholesterol efflux transporter,
potently promoting tumor cell death in a GBM model (Figure 4). Further, GBM is remarkably
dependent on cholesterol for survival, rendering these tumors sensitive to LXR agonist-dependent
cell death, based on identifying and targeting tumor co-dependencies shaped both by aberrant
EGFR-mTOR signaling and the brain’s unique biochemical environment [87]. Recent reports also
demonstrate a novel link between mTOR complexes and lipid metabolism. mTORC2 stimulated
sphingolipid and glycerophospholipid synthesis, and inhibition of fatty acid or sphingolipid synthesis
prevented tumor development, indicating a causal effect in tumorigenesis as well as a novel therapeutic
opportunity [88]. Further, in addition to the role of mTOR a sensor of amino acids and glucose, a recent
study reveals that mTOR also senses the presence of lipids through production of phosphatidic acid,
expanding its role as a metabolic sensor in the cell [89]. Additionally, the combination of an xCT
inhibitor erastin with Torin1 (mTOR kinase inhibitor, which blocks both mTORC1 and mTORC2
activity) resulted in significant GBM cell death, while cell survival was not affected by either drug
alone, indicating that increased xCT activity has a major contribution to glutathione synthesis and
GBM cell survival upon pharmacological mTOR kinase inhibition [67] (Figure 4). Thus, understanding
the regulation of cellular metabolism with mTOR signaling may pave the way for the development of
more effective treatment strategies.
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8. Unanswered Questions on mTOR-Dependent Metabolism in Cancer
There have traditi ally been plenty of the epidemi logical studies endeavoring to reveal the
statistic link between cancer incidence and metabolic factors including obesity, diabetes mellitus, and
Western-type life style and diet. However, the relationship was not usually solid, partly because most
of the studies did not touch on the tumor genotype. Future studies will be necessary to plan the
mechanistic types of studies that will untangle the interaction between nutrients, metabolism, and
cancer biology on a genetic and molecular basis, which will eventually reveal the impact of nutrient
and metabolism on tumor pathogenesis, aggressiveness, and response/resistance to treatment. Thus,
mTOR-dependent metabolism should be evaluated in the specific context of genotype-defined and
nutrient/environment-restricted conditions.
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We have proposed the questions on mTOR-dependent metabolism in cancer, which should
be tackled in the future for achieving the goal of developing novel therapeutic and preventive
strategies against cancer with facilitated metabolism. In order to determine whether accelerated cellular
metabolism is not only a consequence reprogrammed by oncogenic signaling but also potentially
affected by a specific tumor microenvironment, it will be necessary to regulate diet and nutrient levels
in genotyped human and mouse tumor models to assess the impact of metabolism on signal activation,
tumor progression, and response/resistance to treatment. The critical point here is to recognize that
the status of specific nutrients in the tumor microenvironment are not merely a consequence of the
diet but rather established by the intricate interaction between diet uptake, de novo/salvage synthesis,
and cellular utilization [90]. Thus, directly measuring the levels of specific nutrient and tracing their
uptake and utilization in tumor tissue in human and genetically engineered mouse models will be
needed. Importantly, mTOR complexes are one of the critical hubs and nodes integrating nutrient
status and altered growth factor receptor signaling, but understanding how they interact with other
nutrient sensing pathways will also be important.
In addition, to test a hypothesis that mTOR complexes are a key node to integrate growth factor
receptor signaling with nutrient availability, influencing tumor growth and response to treatment,
it will be necessary to study the role of mTOR and its modulation by nutrients in various cancer
types. Furthermore, to test the hypothesis that glucose or amino acid-derived intermediates including
acetyl-CoA and SAM directly contribute to tumor growth and drug resistance, genetic studies will be
needed particularly to confirm the hypothesized importance of histone acetylation, histone methylation,
and DNA methylation and to determine if persistent mTOR signaling is sufficient to maintain tumor
growth and cause drug resistance through metabolic reprogramming and subsequent epigenetic shifts,
for example, by examining the impact of elevated acetyl-CoA and SAM levels on enhancer activation
and transcriptional reprogramming.
9. Conclusions and Future Perspectives
The intricate orchestration of responses that enable cancer cells to meet their demands in a
completely cell-autonomous fashion defines the specificity of metabolic reprogramming in cancer.
A promising and less toxic therapeutic strategy for patients with cancer will be achieved by the
development of inhibitors that target cancer-specific signal transduction and metabolism. However,
that goal is unlikely to be achieved until the impact of cancer-causing driver mutations on metabolic
reprogramming and epigenetic regulation are deeply comprehended, including the flexible ways in
which tumor cells appropriately sense the nutrient status in microenvironment and adapt to changing
conditions, so as to coordinately sustain the constitutive activation of downstream effectors necessary
for tumor cell proliferation and survival. We have herein summarized the recent literature, clearly
pointing out an unanticipated important role for both mTOR complexes in sensing essential nutrients
including glucose and amino acids via cancer metabolic reprogramming, where they integrate aberrant
signaling activities into biochemical reactions and potential transcriptional regulations that drive
tumor progression. We have also highlighted an emerging role for mTORC2 in linking aerobic
glycolytic metabolism with amino acid metabolism, which could potentially be a key mechanism
to exquisitely tilt the balance between dichotomic cellular events essential for tumor cell survival
including cell proliferation and cell protection from oxidative stress. Future endeavors should
be directed to understand how driver mutations in cancer rewire intracellular signaling cascades
to translate biochemical metabolic reactions into global epigenetic ensembles [17]. Cooperative,
multidisciplinary, and translational approaches would be necessary to yield critical insights into the
etiology and pathogenesis of cancer, shed new light on how tumor cells resist molecularly targeted
therapies, and possibly pave the way for the development of more effective signaling-dependent
metabolism-targeted treatments against cancer to achieve the goal of “precision medicine.”
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